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Background: Brain metastasis from gastric cancer is fairly uncommon and prognosis is dismal. We report a case of
early gastric cancer with brain metastasis arising 8 years after gastrectomy.
Case presentation: A 78-year-old Japanese female presented to our hospital complaining of dizziness, 8 years after
undergoing gastrectomy for gastric cancer. Histopathological type of the tumor was well-differentiated adenocarcinoma.
Final TNM classification was T1b(sm1)N0M0, and pathological stage was IA. Further examination revealed a metastatic
tumor in the cerebellum and multiple liver metastases. The brain metastasis was treated using radiotherapy and steroid.
Systemic treatment for liver metastases was performed using the oral fluoropyrimidine drug S-1. Neurological symptoms
decreased, enabling the patient to be discharged from hospital. However, chemotherapy was discontinued due to loss of
appetite and general fatigue. She died 5 months after the diagnosis of brain metastasis due to progressive disease.
Conclusions: Cases of brain metastasis arising 8 years after gastrectomy for early gastric cancer have rarely reported.
Aggressive treatment for brain metastases may be effective for improvement of the damage to neurological function and
quality of life.
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Gastric cancer is one of the most common gastrointes-
tinal tumors in Japan. Outcomes for patients with early
gastric cancer have improved thanks to advances in
diagnosis and treatment. However, patients with unre-
sectable or recurrent gastric cancer still experience poor
outcomes. Recurrence of gastric cancer often appears in
the form of peritoneal dissemination, and liver metasta-
ses, lymph node recurrence and bone metastases are
often seen.
The frequency of brain metastasis from gastric cancer
is less than 1% [1-3]. Almost all brain metastases from
gastric cancer are seen in advanced-stage disease with
concurrent metastasis to other organs. Brain metastasis
after curative gastrectomy for early gastric cancer ap-
pears extremely rare, and to our knowledge, there is no* Correspondence: m1157473@med.osaka-cu.ac.jp
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operation for early gastric cancer. Palliative care is often
performed for the patient with brain metastasis accord-
ing to the other metastasis as terminal stage. However
aggressive treatment such is warranted for brain metas-
tases because of the damage to neurological function
and quality of life (QOL). The present report describes a
case with brain metastases after curative resection for
early gastric cancer.Case presentation
A 78-year-old Japanese female had been diagnosed with
gastric cancer 8 years earlier and underwent distal gas-
trectomy. The tumor size was 45 × 45 mm, and no
lymph node metastases were noted. Histological type of
the tumor was well-differentiated adenocarcinoma. Final
pathological TNM classification was T1b(sm1)N0M0, and
the clinical stage was IA according to the Union for Inter-
national Cancer Control criteria. Postoperative course wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Sagittal view T1-weighted magnetic resonance imaging
(fat suppression) of the brain shows a 2.5-cm tumor with
surrounding edematous change (arrow).
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nual follow-up with blood tests and abdominal computed
tomography (CT). She received no adjuvant chemother-
apy. She was referred to our hospital complaining of dizzi-
ness and an inability to walk. Brain CT revealed a tumor
(diameter, 2.5 cm) with ring enhancement in the cerebel-
lum (Figure 1). Abdominal CT revealed multiple liver me-
tastases. No ascites or peritoneal dissemination was seen.
Magnetic resonance imaging of the head showed an en-
hanced tumor with central necrosis in the cerebellum and
surrounding edematous changes on T1-enhanced imaging
(fat suppression) (Figure 2). Endoscopy and colonoscopy
did not detect any recurrent lesions in the gastrointestinal
tract. Tumor marker levels were as follows: carcinoem-
bryonic antigen, 6.0 ng/ml; and carbohydrate antigen 19–
9, 19 U/ml. Microscopic examination of hematoxylin and
eosin (HE)-stained percutaneous biopsy specimens of
the liver metastasis revealed adenocarcinoma (Figure 3).
Increased uptake was seen in the liver tumors and para-
aortic lymph nodes (standardized uptake values: vermis
cerebellum, 6.7; liver, 5.5-6.2; and para-aortic lymph
node, 2.2) on 18 F-fluorodeoxyglucose-enhanced positron
emission tomography. We thus diagnosed the liver and
brain tumors as metastases derived from gastric cancer.
Radiotherapy for brain metastasis was performed in
conjunction with corticosteroid administration (30 Gy
for whole brain, including metastasis). At 10 weeks after
radiotherapy, the metastatic brain tumor had decreased
in size (Figure 4). Clinical symptoms decreased markedly
after radiotherapy, enabling her to be discharged from hos-
pital. She subsequently received the oral fluoropyrimidineFigure 1 Computed tomography (CT) of the brain shows a
tumor (diameter, 2.5 cm) with ring enhancement in the
cerebellum (arrow).drug S-1 for the treatment of liver and lymph node metas-
tases. The regimen of S-1 consisted of six-week cycles in
which, 100 mg of oral S-1 per body per day was given for
four weeks and no chemotherapy was given for the follow-
ing two weeks. However, chemotherapy was discontinued
after two courses due to fatigue and loss of appetite. The
patient’s performance status subsequently deteriorated, and
she died 5 months after the diagnosis of brain metastasis.
Discussion
In Japan, gastric cancer is the most common digestive
cancer, and the incidence of gastric cancer in Japan isFigure 3 Pathological examination of a biopsy specimen of the
liver tumor shows metastatic adenocarcinoma that is poorly
differentiated with solid and cord-like proliferation
(hematoxylin and eosin, ×200).
Figure 4 At 10 weeks after radiotherapy, CT shows a tumor
reduced in size (arrow).
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26.1 per 100,000 women) [4]. The outcomes of surgical
treatment for early gastric cancer (EGC) are generally
considered satisfactory. However, a small percentage of
patients experience disease recurrence. Sano et al. esti-
mated a recurrence rate for EGC of at least 1.9% by
combining the data from 20 reports in the literature [5].
On the other hand, advanced gastric cancer mostly re-
curs as peritoneal metastasis and often recurs in the
lymph nodes, liver and bones. Brain metastases from
gastric cancer are exceedingly rare. York et al. analyzed
3320 gastric cancer patients treated over a 40-year
period and identified brain metastases in only 24 pa-
tients (0.7%) [1]. Kasakura et al. identified brain metasta-
ses in only 11 of 2322 patients (0.47%) [6]. These cases
involved simultaneous or metachronous metastases from
advanced stage disease. To our knowledge, there is no
report of brain metastasis arising 8 years after curative
operation for early gastric cancer as the present case.
It is not clear the mechanism of metastasis to liver and
brain 8 years after curative resection. These metastases
are hematogenous and might indicate that the cancer is
a systemic disease, not local disease. It has been pointed
out cancer cells are circulating in the peripheral blood
from an early stage. The presence of peripheral blood
circulating tumor cells (CTCs) is a predictor of relapse
or poor prognosis and has documented even in early
stage colon cancer or breast cancer [7-9]. Uen et al. in-
vestigated preoperative and postoperative CTCs in pa-
tients with stage I-III colorectal cancer who underwentcurative resection; preoperative CTCs were detected in
33.3% of patients with stage I disease, and postoperative
CTCs were detected in 6.0% of patients with stage I dis-
ease [8]. We speculate that post operative CTCs are
present in patients with early gastric cancer undergoing
R0 resection and that malnutrition or immune com-
promise promotes the proliferation and metastasis of
CTCs, thereby increasing the risk of tumor recurrence.
Therapy for metastatic brain tumor includes surgical
resection, radiation and chemotherapy or a multidiscip-
linary approach that combines these modalities. Stereo-
tactic radiosurgery, such as cyber knife or gamma knife,
has become the mainstay of therapy for metastatic brain
tumors [10]. However, the response to treatment is poor
among patients with brain metastasis from gastric can-
cer. Most brain metastases from gastric cancer are de-
tected in the advanced stages, with metachronous or
simultaneous metastasis to other organs [1,6]. Therefore
palliative care was performed in many cases. However,
aggressive treatment should be undertaken to improve
the neurological symptoms of brain metastasis if pro-
gression of metastases in other organs can be controlled.
In our case, since performance status (PS) was poor, we
judged there was no surgical indication. Therefore we
selected whole brain radiation therapy. As a result, her
neurological function has recovered dramatically by radi-
ation therapy. From our experience, we consider that ra-
diation therapy is useful for the brain tumor from gastric
cancer in inoperable case.
The mean interval from gastrectomy to the diagnosis
of brain metastasis has been reported as 9.0-9.6 months
[1,6]. Mean survival for patients with brain metastasis
from gastric cancer is approximately 2 months, signifi-
cantly less than the mean survival among patients with
brain metastasis from breast cancer (5.6-6.8 months)
[11,12] or lung cancer (6.9-7.8 months) [13,14]. York et al.
reported that median survival time in patients who re-
ceived whole-brain radiation therapy (WBRT) in conjunc-
tion with corticosteroids was 9 weeks after diagnosis of
brain metastasis, and median survival in patients who
underwent surgical resection of brain metastases in
addition to WBRT and steroids was 54 weeks [1]. Kasa-
kura et al. reported that survival rates were highest for
the resection group, followed by the chemoradiotherapy
group and then the no-treatment group [6]. Median
survival for these groups was 24 weeks (n = 3), 7.4 weeks
(n = 4) and 2.8 weeks (n = 4), respectively.
The most common presenting symptoms for brain me-
tastasis from gastric cancer are weakness (67%), headache
(42%), balance/gait abnormalities (42%), and nausea/em-
esis (38%) [1]. Kasakura et al. reported that all patients
with brain metastasis had stage ≥ III cancer, all had lym-
phovascular invasion or lymph node metastasis, and many
had metastases to other organs [6]. York et al. reported
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showed concurrent systemic metastasis to the lymph
nodes, bones, liver and lungs [1]. Nomura et al. reported a
case of brain metastasis from submucosal gastric carcin-
oma, but that patient had stage IV cancer accompanied by
liver metastasis [15].
No factors that can predict brain metastases have yet
been identified. Alpha-fetoprotein (AFP)-producing gas-
tric cancer with brain metastasis has been reported
[16,17] and AFP may thus be useful as a predictive fac-
tor for brain metastasis.
We often detect metastases to other organs at the
same time as diagnosis of brain metastasis from gastric
cancer. Brain tumor from gastric cancer is thus the end
picture of multi-organ metastasis and carries a poor
prognosis. Cause of death is often metastasis, though
metastasis to the brain is rare. Because neurological
symptoms associated with metastatic brain tumors sig-
nificantly reduce QOL for the patient, aggressive treat-
ment of symptoms is very important to allow the patient
to spend the rest of their life in a meaningful way.
In our case, radiotherapy was treatment of the brain
tumor and S-1 was treatment of the liver tumor. A com-
bination of cisplatin and S-1 chemotherapy is a standard
regimen for unresectable gastric cancer in Japan [18],
but her PS was poor. Therefore we selected S-1 mono-
therapy. Effective chemotherapy for brain tumor is not
known well. Intravenously administered agents do not
generally cross the cerebral parenchyma due to the
blood–brain barrier (BBB). However Kitayama et al. re-
ported a case in which paclitaxel therapy proved effect-
ive against gastric cancer with brain metastasis [19].
Kokufu et al. also reported the usefulness of paclitaxel
for brain metastasis from breast cancer [20].
A major protein constituent in the BBB is P-glycoprotein
(P-gp). Gerstner et al. reported that immunochemical P-gp
expression in the neovasculature of metastatic brain tu-
mors was less than that of gliomas and suggested that
metastatic brain tumors with low P-gp expression might
be more permeable to natural product chemotherapy
drugs than gliomas [21]. Fine et al. reported that the me-
dian concentration of paclitaxel was 2.46-fold higher in the
periphery of metastatic brain tumors as compared with gli-
omas suggesting decreased BBB function likely secondary
to decreased expression of P-gp in neovascular endothelial
cells of metastatic brain tumors [22]. We consider that
since the BBB is damaged in patients with marked brain
metastasis, intravenously administered agents may be able
to cross the cerebral parenchyma. In addition, paclitaxel is
known to act as a radiosensitizer to increase the radiosensi-
tivity of tumor cells. Paclitaxel chemotherapy in combin-
ation with radiation can thus be expected to offer a useful
treatment for brain metastasis. Effect of chemotherapy for
brain tumor should be examined further.Conclusion
Brain metastases arising after gastrectomy for early gas-
tric cancer is extremely rare. Palliative care is often
chosen for brain metastasis according to the other me-
tastasis as terminal stage. However, aggressive treatment
for brain tumors, such as radiotherapy or chemotherapy,
appears useful for improving neurological function and
allowing the patient to spend the rest of their life in a
meaningful way. Patients with a history of gastric cancer
and neurological symptoms should be examined while
keeping the possibility of brain metastasis in mind, be-
cause brain metastasis can arise even in long-term follow-
up after curative resection for early gastric cancer.
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